Peppoloni S, Herberman R B, Gorelik E
Clin Exp Metastasis. 1987 Jan-Mar;5(1):43-56. doi: 10.1007/BF00116625.
The metastatic ability of 3LL tumor following in vitro irradiation with ultraviolet (u.v.) light was studied. Tumor cells were exposed to two courses of u.v.-irradiation (3LL X 2u.v. cells) and after two weeks of culture they were inoculated intravenously (i.v.) into syngeneic mice. These cells produced significantly fewer pulmonary metastases than the untreated population. In addition, intrafootpad (i.f.p.) injections of 3LL X 2u.v. cells into immunocompetent animals induced tumors only in 40 per cent of recipients. Interestingly, in normal mice with progressively growing 3LL X 2u.v. tumors, the formation of spontaneous pulmonary metastases was prevented, whereas metastatic foci were observed in 70 per cent of the nude recipients. The metastatic properties of u.v.-treated tumor cells were further analysed by using individual clones with varying immunogenicity. We found that variants with augmented immunogenicity also showed a parallel decrease in metastatic potential. Studies on H-2 antigen expression in different clones revealed that immunogenic and low metastatic variants expressed levels of H-2 antigens higher than the tumorigenic and metastatic clones. Finally, by using cyclophosphamide (Cy) treatment and adoptive transfer of immune spleen cells were able to eradicate macroscopic 3LL pulmonary metastasis. These results demonstrate that the decrease of metastatic ability in u.v.-treated cells was mainly due to an increase in their immunogenicity and H-2 antigen expression.
研究了紫外线(u.v.)体外照射后3LL肿瘤的转移能力。将肿瘤细胞暴露于两个疗程的紫外线照射(3LL X 2u.v.细胞)下,培养两周后静脉内(i.v.)接种到同基因小鼠体内。这些细胞产生的肺转移灶明显少于未处理的细胞群体。此外,将3LL X 2u.v.细胞经足垫内(i.f.p.)注射到免疫活性动物体内,只有40%的受体诱导产生肿瘤。有趣的是,在患有逐渐生长的3LL X 2u.v.肿瘤的正常小鼠中,自发性肺转移的形成受到抑制,而在70%的裸鼠受体中观察到转移灶。通过使用具有不同免疫原性的单个克隆进一步分析了经紫外线处理的肿瘤细胞的转移特性。我们发现免疫原性增强的变体其转移潜能也平行降低。对不同克隆中H-2抗原表达的研究表明,免疫原性和低转移性变体表达的H-2抗原水平高于致瘤性和转移性克隆。最后,通过使用环磷酰胺(Cy)治疗和免疫脾细胞的过继转移能够根除肉眼可见的3LL肺转移灶。这些结果表明,经紫外线处理的细胞转移能力的降低主要是由于其免疫原性和H-2抗原表达的增加。